Australia’s Biota, GSK Settle Dispute Over Relenza Promotion
This article was originally published in PharmAsia News
Executive Summary
Biota Holdings of Australia and GlaxoSmithKline have reached a $19 million settlement of a dispute over GSK's method of promoting the Australian firm's Relenza (zanamivir) flu drug. Biota had licensed the drug to GSK for global marketing in 2000, but later accused the U.K. firm of failing to promote it properly. Biota sued GSK for $683 million, but settled for less based on advice a trial would be delayed for a long time at greater cost and risk to Biota. Biota said the two firms would resume their cooperation in promoting the drug. (Click here for more